Pfizer wins bid to invalidate GSK's patents over RSV vaccine

Pfizer won a bid in a London court to invalidate two of GSK Plc’s (NYSE:GSK) patents relating to its respiratory syncytial virus (RSV) vaccine.

Pfizer and GSK are competing to tap into the respiratory syncytial virus (RSV) vaccine market, which could exceed $10 billion by 2030.

In August 2023, GSK sued Pfizer in Delaware court, alleging that Pfizer’s RSV vaccine Abrysvo violates GSK’s four patent rights in its RSV shot Arexvy.

In the lawsuit, GSK said that Pfizer began working on its RSV program as early as 2013, at least seven years after GSK.

The European pharma giant also says that Pfizer knew of at least the '002 Patent (which is entitled Recombinant RSV Antigens) since at least October 2019, when Pfizer filed an opposition in the European Patent Office claiming that a European counterpart to the '002 Patent is invalid.

In June 2022, Pfizer also filed an action against GSK in the Royal Courts of Justice in London, claiming that European counterparts to the '002 and '239 Patents (RSV F Protein Compositions and Methods for Making Same) are invalid.

The lawsuit said Pfizer had known of GSK’s patented technology since at least 2019 when it began challenging the validity of European versions of the patents.

Reuters noted that a GSK spokesperson stated that the ruling “does not affect our ability to launch and market Arexvy globally, including in the UK.” The company remains confident in the validity of its patents, which it believes Pfizer has infringed and plans to appeal the decision.

In response, Pfizer expressed satisfaction with the court’s verdict. A spokesperson said, “Pfizer is pleased with the UK High Court’s decision, which found certain GSK patents related to RSV technology to be invalid and not infringed.”

https://finance.yahoo.com/news/pfizer-wins-london-court-battle-175604105.html